Kaohsiung Medical University

Kaoshiung Medical University

Suh-Hang Hank Juo

Yung-Song Wang

Jaw-Yuan Wang

Edward Hsi

I-Ping Yang

Hsiang-Lin Tsai

Chung-Ling Liang

Ku-Chung Chen

Yang-Chang Wu

Fang-Rong Chang

Ying-Chi Du

An-Shen Lin

Tusty-Jiuan Hsieh

Hsin-Yun Cheng

I-Chung Hsieh

Ching-Yu Hu

The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.

MicroRNA-328 anti-sense composition and therapeutic use

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4'-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR&#x3b3; inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR&#x3b3; ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1&#x3b2; (IL-1&#x3b2;) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

Composition for treating atherosclerosis and a preparation method thereof

The present disclosure provides a method for treating and/or preventing myopia, including: administering an RNA interference (RNAi) to a subject, wherein the RNA interference is capable of counteracting another RNA interference, and the other RNA interference is an RNA interference capable of inhibiting an expression of PAX-6 gene, and the RNA interference capable of inhibiting an expression of PAX-6 gene comprises microRNA-328.

Method for treating and/or preventing myopia

The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection, stroke or ischemic stroke can be prevented and/or treated.

Methods of using microRNA 195 in providing neuroprotection

The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer.

MicroRNA based method for anti-colorectal cancer effects and prognosis of colorectal cancer

There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

Method of therapy and diagnosis of atherosclerosis

The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector.

Method for treating atherosclerosis

MicroRNA-based method for anti-colorectal cancer effects and prognosis of colorectal cancer

The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.

Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Using the BICD1 gene as a method for diagnosing myopia and/or myopia related complications is provided. The method includes obtaining a biological sample from a subject, and determining at least one SNP genotype in the BICD1 gene in the biological sample, wherein the presence of the SNP genotype indicates that the subject is susceptible to myopia. The SNP genotype is selected from the group consisting of SNPs rs7966276, rs1151029, rs2650122, and rs10771923. In addition, the present invention also provides a method of screening a material for preventing, treating myopia, and a method of assessing a subject for probability of response to a myopia therapeutic agent.

Growing community of inventors

Kaohsiung, Taiwan

Suh-Hang Hank Juo